62/100BIf you had invested in Natera ago, it would be worth $36,766 today, against $4,128 in SPY and $6,186 in QQQ.
Arincen ScoreBeta
Six parts of the company, five checks each, from its own reported figures. A part scores the checks it passes out of 10; the score is their average out of 100.
Profitability4
Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.
Cash3.3
Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.
Valuation—
Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.
Growth10
Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.
Financial strength7.5
Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.
Shareholders—
Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.
Figures to FY2025; the price as of today.
Natera key facts
- Style
- Speculative (losing money)
- Day range
- 304.01 – 327.53
- 52-week range
- 181.00 – 437.41
- Market capitalization
- 44.73B USD
- EPS
- -1.14
- Volume
- 257,202
- Beta
- 1.53
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Steven Leonard Chapman
- Employees
- 6K
- Website
- natera.com
- IPO date
- 1 Jul 2015
Natera earnings
Revenue
EPS
| Period | Report date | EPS estimate | Reported EPS | Surprise | EPS growth | Revenue estimate | Reported revenue | Surprise | Revenue growth |
|---|---|---|---|---|---|---|---|---|---|
| Q2 FY2028 | 0.18 | — | — | — | 1.02B | — | — | — | |
| Q1 FY2028 | 0.16 | — | — | — | 958.06M | — | — | +17.74% | |
| Q1 FY2027 | -0.25 | — | — | — | 813.69M | — | — | +16.80% | |
| Q4 FY2026 | -0.11 | — | — | -130.03% | 749.53M | — | — | +12.63% | |
| Q3 FY2026 | -0.28 | -0.42 | -49.34% | — | 707.54M | 793.98M | +12.22% | +34.08% | |
| Q2 FY2026 | -0.49 | -0.47 | +4.85% | — | 661.24M | 752.75M | +13.84% | +37.71% | |
| Q1 FY2026 | -0.54 | -0.56 | -3.28% | — | 617.10M | 696.64M | +12.89% | +38.82% | |
| Q4 FY2025 | -0.51 | 0.35 | +168.35% | — | 604.04M | 665.50M | +10.18% | +39.79% | |
| Q3 FY2025 | -0.39 | -0.64 | -65.94% | — | 513.45M | 592.18M | +15.33% | +34.66% | |
| Q2 FY2025 | -0.62 | -0.74 | -20.24% | — | 476.26M | 546.60M | +14.77% | +32.24% |
| Period | EPS estimate | Reported EPS | Surprise | EPS growth | Revenue estimate | Reported revenue | Surprise | Revenue growth |
|---|---|---|---|---|---|---|---|---|
| FY2028 | 1.27 | — | — | — | 4.26B | — | — | +21.13% |
| FY2027 | -0.37 | — | — | — | 3.52B | — | — | +20.89% |
| FY2026 | -1.45 | — | — | — | 2.91B | — | — | +26.20% |
| FY2025 | -2.40 | -1.53 | +36.18% | — | 2.24B | 2.31B | +2.83% | +35.90% |
| FY2024 | -1.50 | -1.53 | -2.17% | — | 1.65B | 1.70B | +2.73% | +56.75% |
| FY2023 | -3.96 | -3.79 | +4.27% | — | 1.07B | 1.08B | +1.17% | +31.99% |
| FY2022 | -5.60 | -5.57 | +0.58% | — | 819.43M | 820.22M | +0.10% | +31.13% |
Natera analyst forecast
Analysts' 1-year price targets range from 245.00 to 500.00, with an average of 393.16.
| Strong buy | 0 | |
| Buy | 14 | |
| Hold | 2 | |
| Sell | 0 | |
| Strong sell | 0 |
12-month price target
| Highest target | 500.00 |
| Average target | 393.16 |
| Lowest target | 245.00 |
| Current price | 310.29 |
Natera valuation
- Forward P/E (FY2028)
- 243.41
- Price to sales (TTM)
- 15.38
- Price to book
- 23.92
Capital structure
Valuation over time
Natera against its own history
Each figure in the latest fiscal year against the same figure from FY2021 to FY2025: the range, its median (the line) and the latest (the dot, green on the good side of the median). The P/E is today's against its daily readings of five years.
Its peers: IDEXX Laboratories, Agilent Technologies, Waters, IQVIA Holdings, Mettler-Toledo International, and Illumina, the US Medical - Diagnostics & Research companies closest to it in size, each in its own latest fiscal year: their median (the line) and its rank among them, first being the best.
- Gross marginHighest in 5 years64.8%44.4%64.8%Against its peers: 2 of 7Peers' median 58.6%
- Operating marginAbove its median-13.4%-74.8%-13.1%Against its peers: 7 of 7Peers' median 24.5%
- Net marginHighest in 5 years-9.0%-75.4%-9.0%Against its peers: 7 of 7Peers' median 19.9%
- Return on equityHighest in 5 years-12.2%-77.6%-12.2%Against its peers: 6 of 6Peers' median 25.1%
- Free cash flow marginHighest in 5 years4.7%-60.2%4.7%Against its peers: 7 of 7Peers' median 19.1%
- Revenue growthAt its median35.9%31.1%60.0%Against its peers: 1 of 7Peers' median 6.3%
- Current ratioLowest in 5 years3.393.394.99Against its peers: 1 of 7Peers' median 1.45
Peers: US companies of the same industry (of its sector when the industry has too few) from a tenth to ten times its market value, the six closest in size. Updated weekly.
Natera growth and profitability
- Revenue (TTM)
- 2.91B USD
- Net income (TTM)
- -164.71M USD
- Gross margin
- 65.24%
- Operating margin
- -8.95%
- Net margin
- -5.66%
Revenue / Net income
Natera revenue breakdown
By product
| Segment | Revenue | Share of revenue | Change on the year |
|---|---|---|---|
| Product | 2.30B | 99.6% | +36.2% |
| Licensing and other | 10.29M | 0.4% | -13.0% |
By region
| Region | Revenue | Share of revenue | Change on the year |
|---|---|---|---|
| United States | 2.26B | 98.2% | +36.6% |
| Europe, Middle East, India, and Africa | 24.48M | 1.1% | — |
| Americas, excluding U.S. | 9.35M | 0.4% | +41.3% |
| Asia Pacific and Other | 8.01M | 0.3% | -7.5% |
Natera financial health
- Cash and short-term investments
- 1.10B USD
- Total debt
- 222.91M USD
- Net cash
- 874.28M USD
- Free cash flow (TTM)
- 52.47M USD
- Current ratio
- 2.81
- Debt to equity
- 0.12
- Piotroski score
- 2 / 9
- Altman Z-score
- 35.55
Cash, debt and free cash flow
Natera ownership
- Institutions
- 96.26%
- Institutional holders
- 886 (+94)
- Free float
- 93.58%
Who owns the shares
Shares free to trade
Closely held shares belong to insiders, founders and owners of more than 5%, and seldom change hands. The free float is the rest: the shares anyone can buy and sell.
Insider trading
| Quarter | Purchases | Sales | Shares acquired | Shares disposed of |
|---|---|---|---|---|
| Q4 2026 | 0 | 85 | 50.00K | 143.10K |
| Q3 2026 | 0 | 139 | 20.00K | 276.86K |
| Q2 2026 | 0 | 124 | 87.40K | 364.12K |
| Q1 2026 | 0 | 116 | 701.15K | 865.71K |
Shares outstanding
Source: Financial Modeling Prep
